YMAB vs. MLYS, ETNB, COLL, DYN, ELVN, RCUS, CMRX, CDMO, SYRE, and NTLA
Should you be buying Y-mAbs Therapeutics stock or one of its competitors? The main competitors of Y-mAbs Therapeutics include Mineralys Therapeutics (MLYS), 89bio (ETNB), Collegium Pharmaceutical (COLL), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Arcus Biosciences (RCUS), Chimerix (CMRX), Avid Bioservices (CDMO), Spyre Therapeutics (SYRE), and Intellia Therapeutics (NTLA). These companies are all part of the "pharmaceutical products" industry.
Y-mAbs Therapeutics vs.
Mineralys Therapeutics (NASDAQ:MLYS) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and institutional ownership.
Mineralys Therapeutics has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Y-mAbs Therapeutics' return on equity of -24.61% beat Mineralys Therapeutics' return on equity.
Y-mAbs Therapeutics received 119 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 63.30% of users gave Y-mAbs Therapeutics an outperform vote.
Y-mAbs Therapeutics has higher revenue and earnings than Mineralys Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Mineralys Therapeutics had 5 more articles in the media than Y-mAbs Therapeutics. MarketBeat recorded 8 mentions for Mineralys Therapeutics and 3 mentions for Y-mAbs Therapeutics. Mineralys Therapeutics' average media sentiment score of 1.06 beat Y-mAbs Therapeutics' score of 1.06 indicating that Mineralys Therapeutics is being referred to more favorably in the media.
Mineralys Therapeutics has a beta of -0.39, indicating that its share price is 139% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.
Mineralys Therapeutics currently has a consensus price target of $33.00, suggesting a potential upside of 136.90%. Y-mAbs Therapeutics has a consensus price target of $18.30, suggesting a potential upside of 247.25%. Given Y-mAbs Therapeutics' higher probable upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Mineralys Therapeutics.
84.5% of Mineralys Therapeutics shares are held by institutional investors. Comparatively, 70.8% of Y-mAbs Therapeutics shares are held by institutional investors. 33.2% of Mineralys Therapeutics shares are held by insiders. Comparatively, 22.5% of Y-mAbs Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Y-mAbs Therapeutics beats Mineralys Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Y-mAbs Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Y-mAbs Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:YMAB) was last updated on 4/15/2025 by MarketBeat.com Staff
